

**LISTING OF THE CLAIMS**

A listing of the claims is provided for the convenience of the Examiner. No amendments have been made to the claims.

1-13. (Canceled)

14. (Previously presented) A method for treating a mood disorder in a human patient, which comprises administering to a patient in need thereof a therapeutically effective amount of cannabichromene (CBC)

wherein the CBC is substantially pure or is an extract from a cannabis plant that contains greater than or equal to 30% CBC of the total cannabinoid content, and

wherein the mood disorder is morbid or clinical depression, unipolar mood disorder, bipolar mood disorder, syndromal depression, panic disorder or anxiety.

15.-17. (Canceled)

18. (Previously presented) The method according to claim 14 wherein the CBC is present in an extract of at least one cannabis plant.

19. (Previously presented) The method according to claim 14, wherein the CBC is administered nasally, sublingually, buccally, topically, orally, rectally, intravenously, intra-peritoneally, intra-muscularly, subcutaneously, transdermally, intra-vaginally, intra-urethrally, by nebuliser, as inhaled vapour or by installation directly into the bladder.

20.-24. (Canceled)

25. (Previously presented) The method according to claim 18, wherein the extract comprises substantially all the naturally occurring cannabinoids in said at least one cannabis plant.

26. (Previously presented) The method according to claim 18, wherein the extract is enriched for CBC.

27. (Previously presented) The method according to claim 14, wherein the CBC is administered in an isolated and substantially pure form.

28. (Previously presented) The method according to claim 14, wherein the CBC is administered together with one or more pharmaceutically acceptable diluents, excipients or carriers.